|Articles|March 1, 2009

Pharmaceutical Executive

  • Pharmaceutical Executive-03-01-2009
  • Volume 0
  • Issue 0

GSW Worldwide for MGI Pharma/Eisai's PONV

Author(s)Brittany Agro

To educate anesthesiologists that post-operative nausea and vomiting (PONV) is "no fun for anyone," GSW Worldwide created WoozyWorld.com, a "non-amusement" that highlights the need for MGI Pharma's 72-hour antiemetic Aloxi.

WOOZYWORLD

GSW Worldwide

BRAND Market education for PONV CLIENT MGI Pharma/Eisai FROM LEFT: (Seated): Sean Cowan, creative director, digital wave; Kristan Early, vice president, creative director; (Standing): Dean Tepper, senior vice president, group creative director; Seth Quillin, senior vice president, digital operations

To educate anesthesiologists that post-operative nausea and vomiting (PONV) is "no fun for anyone," GSW Worldwide created WoozyWorld.com, a "non-amusement" that highlights the need for MGI Pharma's 72-hour antiemetic Aloxi. The team unveiled the unmistakable (yet unbranded) site before the drug's March 2008 launch. "Creatively, we gave WoozyWorld a darker, tongue-in-cheek edge," says Sean Cowan, creative director, digital wave. They drew inspiration from the retail industry—which is more forward-looking than the pharmaceutical space—to create great, engaging content.

WoozyWorld includes information on the very real consequences of patients' post-operative side effects—with the goal to "make [anesthesiologists] care a little bit longer." "When patients undergo anesthesia, all anesthesiologists really care about is the first 24 hours after surgery," says Kristan Early, vice president, creative director. "Once patients are discharged, anesthesiologists feel their job is done. But in reality, a patient can still become sick once they arrive home or even days later."

Articles in this issue


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.